Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Inventory (2019 - 2025)

Karyopharm Therapeutics' Inventory history spans 7 years, with the latest figure at $4.0 million for Q4 2025.

  • For Q4 2025, Inventory fell 14.79% year-over-year to $4.0 million; the TTM value through Dec 2025 reached $4.0 million, down 14.79%, while the annual FY2025 figure was $4.0 million, 14.79% down from the prior year.
  • Inventory reached $4.0 million in Q4 2025 per KPTI's latest filing, up from $4.0 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $5.0 million in Q2 2025 to a low of $2.8 million in Q1 2024.
  • Average Inventory over 5 years is $3.9 million, with a median of $3.9 million recorded in 2021.
  • Peak YoY movement for Inventory: soared 221.03% in 2021, then fell 27.96% in 2023.
  • A 5-year view of Inventory shows it stood at $4.1 million in 2021, then rose by 2.87% to $4.2 million in 2022, then decreased by 27.96% to $3.0 million in 2023, then skyrocketed by 55.73% to $4.7 million in 2024, then fell by 14.79% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Inventory are $4.0 million (Q4 2025), $4.0 million (Q3 2025), and $5.0 million (Q2 2025).